This study will evaluate the efficacy and safety of siltuximab compared with normal saline in
combination with standard of care (SOC) in selected hospitalized patients with COVID-19
previously treated with corticosteroids or another respiratory virus infection associated
with acute respiratory distress syndrome (ARDS) and elevated C-reactive protein (CRP) levels.